A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
收藏NIAID Data Ecosystem2026-03-12 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2389247
下载链接
链接失效反馈官方服务：
资源简介：
* To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies.
* To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with other cancer therapies.
* To evaluate the antitumor activity of ERAS-007 in combination with other cancer therapies.
* To evaluate the PK profiles of ERAS-007 and other cancer therapies when administered in combination.
* 评估ERAS-007递增剂量联合其他癌症疗法治疗晚期胃肠道（GI）恶性肿瘤受试者的安全性与耐受性。
* 确定ERAS-007联合其他癌症疗法给药的最大耐受剂量（Maximum Tolerated Dose, MTD）和/或推荐剂量（Recommended Dose, RD）。
* 评估ERAS-007联合其他癌症疗法的抗肿瘤活性。
* 评估ERAS-007与其他癌症疗法联合给药时的药代动力学（Pharmacokinetics, PK）特征。
创建时间：
2021-09-15
